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Abstract:  
The present investigation concerns design and evaluation of bilayer floating tablets of Diltiazem HCl Diltiazem HCl is 
Class I drug, though its reported bioavailability is only 40 %. It is having very short half life of 3 to 4 hrs. Hence many 
sustained release formulations were developed for Diltiazem HCl.  
 A direct compression method was used to formulate all batches. 32 factorial design was applied to study % cumulative 
drug release and hardness. Super disintigrants like Sodium starch glycolate was used for immediate release layer and 
HPMC K200 M, Xanthan gum like polymers were used in floating layer for sustain release layer.Optimisation study 
was performed by using design expert software. Successful formulation was developed having floating lag time as low 
as 14 sec and drug release was sustained up to 12 hrs.  A biphasic drug release can be obtained by using bilayer 
tableting technology which involved compression of immediate and sustained release layer together. The variables 
HPMC K200M and  Xanthan Gum evaluated in this study exhibited significant affected the release profile. 
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INTRODUCTION: 
The oral route is the most promising and convenient 
route of drug administration. Conventional immediate 
release system achieves as well as maintains the drug 
concentration within the therapeutically effective 
range, but one has to take such formulations several 
times a day. This results in significant fluctuations in 
plasma drug levels and also the frequency of 
administration leads to patient non-compliance. 
Recently, several technical advancements in the 
pharmaceutical field have led to the development of 
many novel drug delivery systems that could 
revolutionize the method of medication and provide a 
number of therapeutic benefits [1,2]. 
Floating Drug Delivery Systems  
Floating Drug Delivery Systems (FDDS) have a bulk 
density lower than gastric fluids thus, remain buoyant 
in the stomach for a prolonged period of time, without 
affecting the gastric emptying rate. While the system is 
floating on the gastric contents, the drug is released 
slowly and almost completely at a desired rate from the 
system. After the release of the drug, the residual 
system becomes liable to be emptied from the stomach.  
Bilayered Tablets 
A bilayered tablet is one made up of two separate 
layers, with each layer intended for a specific result, 
layers can be formulated to separate physically or 
chemically incompatible ingredients or to produce 
repeat action or to dissolve at different times or to 
deliver the product to different locations or to give 
different pharmacological effects [3]. 
The biphasic system may contain one or two drugs for 
immediate release and sustained release layer 6,7,8,9 
Diltiazem HCl is among the most extensively 
prescribed calcium channel blocker for hypertension & 
angina pectoris. The plasma half life of diltiazemHCl is 
3 to 4 hours. It is BCS class I drug with high solubility 
and high permeability, belonging to the 
benzothiazepine family. Diltiazem HCl undergoes an 
extensive biotransformation, mainly through 
cytochrome P-450 CYP3A, [2] which results in less 
than 4% of its oral dose being excreted unchanged in 
urine. Bioavailability of diltiazem HCl is 30-40% 
owing to an important first pass metabolism.It has an 
elimination half-life of 3.5 hours and has an absorption 
zone from the upper intestinal tract above the 
absorption zone. Diltiazem HCl requires multiple daily 
drug dosage in order to maintain adequate plasma 
concentrations. Therefore, it is a suitable model 
candidate for gastroretentive formulation [10-12]. 
MATERIALS AND METHOD 
Diltiazem HCl was obtained as a gift sample from J.B. 
Chemicals Pvt.ltd. Ankleshwar, Gujarat. HPMC 
K200M, Xanthan gum, Sodium starch glycolate, 
Calcium phosphate, Sodium bicarbonate, Lactose, Mg. 
stearate, Talc. From Research Lab Fine Chem. Ltd. 
Mumbai. 
Formulation Development 
Bilayer tablets of diltiazem HCl contains two layers i.e. 
immediate release layer and sustained release layer. 
Both layers separately optimized. Accurately weighed 
150 mg of immediate release blend and 260 mg of 
sustained release blend individually.  Various batches 
of bilayer floating tablets were prepared by direct 
compression method. Initially, immediate release layer 
blend was fed manually in the die, compressed at low 
compression force to form uniform layer. Subsequently 
sustained release layer was added over it, completely 
compressed on bilayer tableting machine (Rimek Mini 
Press-II, Karnavati Engineering Ltd.) by using 09 mm 
flat punch [14]. 
Table1: Formulation of bilayer floating tablet 
Ingredients                       
( mg/ Tablet) 
Formulation Code 
B1 B2 B3 B4 B5 B6 B7 B8 B9 
Immediate release layer 
Diltiazem 
Hydrochloride 
30 30 30 30 30 30 30 30 30 
Sodium starch 
glycolate 
5 8 6 5 8 6 5 8 7 
Calcium phosphate 113 110 112 113 110 112 113 110 111 
Mg. sterate 1 1 1 1 1 1 1 1 1 
Talc 1 1 1 1 1 1 1 1 1 
Sustaine release layer 
Diltiazem 
Hydrochloride 
90 90 90 90 90 90 90 90 90 
HPMC K200M 60 70 80 60 70 80 60 70 80 
Xanthum gum 10 10 10 20 20 20 30 30 30 
Citric Acid 10 10 10 10 10 10 10 10 10 
Sodium Bicarbonate 15 15 15 15 15 15 15 15 15 
Lactose 27.5 35.5 47.5 57.5 47.5 37.5 67.5 57.5 47.5 
Mg. stearate 5 5 5 5 5 5 5 5 5 
Talc 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
TOTAL 410 410 410 410 410 410 410 410 410 
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Evaluation of Bilayer Floating Tablet 
Hardness (Lachman et al., 1990) 
Tablet requires certain amount of strength or hardness, 
measured by Monsanto hardness tester.  Ten tablets 
were randomly picked from each formulation and 
evaluated for hardness during manufacturing and 
expressed in Kg/cm2 . 
Friability 
Friability was performed by using Roche friabilator; 
normally preweighed 20 tablets were placed in the 
plastic chamber of friabilator. This was then operated 
for 100 revolutions. Tablets dropping from a distance 
of six inches with each revolution. Tablets are then 
dusted and reweighed. 
                                    Initial wt. – Final wt. 
                                            Initial wt. 
 Disintegration Test (IP 1996) 
Six tablets were selected randomly from each batch for 
the disintegration test. Disintegration test was 
performed in simulated gastric fluid using Electrolab 
Disintegration tester (USP). Disintegration time (DT) 
was measured for immediate release layer tablets. 
 Drug content uniformity 
Ten tablets were finely powdered and an amount 
equivalent to 40 mg of Diltiazem HCL was accurately 
weighed and transferred to a 100 mL volumetric flask, 
then 70 mL of methanol was added. The flask was 
shaken for 10 min. Finally, the volume was made up to 
the mark with methanol. The mixture was then filtered 
and 1 mL of the filtrate was suitably diluted with 
methanol to obtain a solution containing about 40 μg 
mL–1 of Diltiazem hydrochloride and analyzed for 
Diltiazem hydrochloride content  at 236 nm using a 
double beam UV/Visible and methanol as blank. 
 Weight Variation (Lachman et al., 1990) 
Twenty tablets were selected randomly and weighed 
individually. Calculated average weight and compared 
the individual tablet weight to the average 
Table 2:Weight variation tolerances for uncoated 
tablets 
Average weight of tablets 
(mg) 
Maximum percent 
difference allowed 
130 or less 
130 – 324 
More than 324 
10 
7.5 
5 
 
 
 Thickness and Diameter 
Thickness and diameter of tablets were accurately 
measured by using digital verniercaliper . 
In-vitro Buoyancy Studies:  
The in-vitro buoyancy was determined by floating lag 
time. The time required for the tablet to rise to the 
surface and float was determined as floating lag time. 
In this the tablets were placed in 100 ml beaker 
containing 0.1 N HCL. 
In-vitro Drug Release Study 
In vitro drug release of Diltiazem hydrochloride was 
determined using a USP (XXI) six stage dissolution 
rate test apparatus I (VeegoScientific) at 50 rpm. The 
dissolution rate was studied using 900 ml of 0.1 N 
Hydrochloride (pH 1.2). The temperature was 
maintained at 37± 0.20°C. The sample (5 mL) was 
withdrawn at different time intervals, i.e. 
5,10,15,20,25,30 60, 120, 180, 240, 300, 360, 480, 600 
and 720 min, filtered through Whatman filter paper and 
replaced by an equal volume of dissolution medium. 
Samples were suitably diluted and analyzed for 
propranolol hydrochloride content at 236 nm. 
RESULTS AND DISCUSSION: 
Preformulation study  
Identification and characterization of drug  
Organoleptic properties  
Diltiazem HCl is a white crystalline powder with no 
odor. 
 
Melting point  
Melting point of Diltiazem HCl was found in the range 
of 210-212°C, which complies with given literature 
value (211°C).  
 
UV spectra  
Diltiazem hydrochloride methanolic solution was 
scanned at 400 nm to 200 nm, one maximas was 
observed at 236 nm. This was confirmed with reported 
UV spectrum of Diltiazem HCL. 
 
Fig 1: Spectrum of Diltiazem HCl at λ max 236 nm 
Infrared Spectrum 
The FT-IR spectrum was measured in the solid state as 
potassium bromide dispersion. The FT-IR spectrum of 
Diltiazem hydrochloride presented in Figure 2 
× 1100 F (%) 
= 
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Fig 2: FT-IR spectrum of Diltiazem hydrochloride 
 
Drug-Polymers Interaction Study 
The FT-IR spectrum of drug and polymers revealed 
that major frequencies of functional groups of pure 
drug remain intact in granules containing different 
polymers; hence, there is no major interaction between 
the drug and polymers used in the study. 
 
Fig 3: FT-IR spectrum of Diltiazem HCL and HPMC K200M 
 
Fig 4: FT-IR spectrum of Diltiazem HCL and Xanthan gum 
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Fig. 5: FT-IR spectrum of mixture of bilayer floating tablet of Diltiazem HCL 
Table 3: FTIR peaks of various functional groups of Diltiazem HCl 
Sr. 
No. 
Energy (wave numbers cm-
1) 
Assignment 
 Reported29 Sample  
1  3056  3055.24  Aromatic C-H stretch  
2  3035  3034.03  Aromatic C-H stretch  
3  2966  2966.52  Aliphatic C-H stretch  
4  2837  2837.29  O-CH3-CH stretch  
5  2393  2351.23  Amine HCl –N stretch  
6  1743  1745.58  Acetate C=O stretch  
7  1679  1680  Lactum C=O stretch  
8  1839  1905  O- substituted Aromatic C-H stretch  
9  781  778  P- substituted out of plane deformation  
Differential Scanning Calorimetry  
DSC thermogram of Diltiazem HCl showed 
endothermic peak of fusion, having peak maximum of  
 
218.84°C. This was in accordance with the reported. 
DSC thermogram is shown in Figure. 6 
 
Fig 6: DSC Thermogram of Diltiazem HCL 
 
 
 
 
 
 
Fig 7: DSC Thermogram of Diltiazem HCL + HPMC K200M +Xanthan gum +Excipients 
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Table 4: Evaluation of bilayer floating tablet factorial design batches B1-B9 
Batches Weight 
Variation* 
(mg) 
Thickness* 
(mm) 
Hardness 
(Kg/cm2) 
Friability 
(%) 
Drug Content 
Uniformity* (%) 
B1 408.1±3.49 2.5 5.5 0.127±0.015 98.27±1.26 
B2 404.9±3.30 2.5 5.5 0.728±0.021 97.11±0.56 
B3 405.4±2.68 2.0 5.5 0.519±0.013 97.46±0.83 
B4 403.40±3.18 2.5 6.0 0.224±0.012 98.57±0.63 
B5 407.65±1.46 3.0 6.5 0.041±0.022 97.89±0.94 
B6 406.40±1.60 2.5 6.0 0.037±0.021 96.49±0.61 
B7 406.15±2.08 2.5 5.5 0.054±0.011 99.63±0.79 
B8 405.40±2.16 2.0 5.8 0.022±0.020 98.84±0.53 
B9 404.15±1.42 2.0 5.5 0.264±0.030 98.73±0.81 
The data are presented as (n = 3) mean value ± S.D. 
Table 5: In-vitro buoyancy study of bilayer floating tablets 
Formulation  
batch code 
Floatinglag time(sec) Total floating 
Time(hrs) 
B1 17.23±0.52 12 
B2 15.00±1.12 12 
B3 14.43±0.47 12 
B4 17.00±1.30 12 
B5 15.66±1.08 12 
B6 16.00±1.40 12 
B7 16.56±0.15 12 
B8 15.56±1.52 12 
B9 17.68±1.55 12 
 
The in-vitro dissolution study of bilayer floating 
tablets of batches B1-B9 
The in-vitro dissolution study of Diltiazem 
hydrochloride bilayer floating tablets was carried out  
 
by using USP dissolution type II apparatus (Paddle) 
(VeegoScientific, DA-6D) 
 
 
 
Fig 7: Comparison of the release profiles of bilayer floating tablets of batches B1 to B3. 
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Fig 8: Comparison of the release profiles of bilayer floating tablets of batches B4 to B6. 
 
 
 
Fig 9: Comparison of the release profiles of bilayer floating tablets of batches B7 to B9. 
 
Data Analysis 
Table 6: In vitro Drug release data Analysis 
 
Batch Zero order First order Matrix Korsmeyer-
peppas 
Hixson-Crowell 
B7 R2 Slope R2 Slope R2 Slope R2 Slope R2 Slope 
0.8980 0.453 0.8077 4.332 0.9679 12.178 0.9574 10.481 0.8971 6.422 
n=11.434 
 
Optimisation 
Table 7: Result of ANOVA 
Response  model Sum of 
square 
Degree of 
freedom 
Mean 
square 
F 
value 
P value R  
square 
Model 
significant/non-
significant 
%Drug release 
(hours) 
811.05 12 159.07 19.25 0.0006 0.9322 Significant 
Hardness 
(Kg/cm2) 
1.26 12 0.243 18.34 0.0007 0.9291 Significant 
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Fig 9: A response surface plot showing effect of concentration of independent     variables on the % Drug release. 
 
Fig 10: A counter plot showing relationship between various levels of independent variables to gain fixed value of 
% Drug release. 
 
Fig 11: A response surface plot showing effect of concentration of independent variables on the Hardness. 
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Fig 12: A counter plot of showing relationship between various levels of independent variables to gain fixed value 
of Hardness. 
Final Equation in Terms of Coded Factors: 
% Drug 
release 
  = + 94.23 +0.89* A +0.85* B -3.94*AB -5.26*A2  -9.00*B2            (1) 
Final Equation in Terms of Coded Factors: 
Hardness   = + 6.10 + 0.17* A +0.30* B-0.10*AB-0.16*A2 +0.019*B2             (2) 
 
Stability Study 
After storage the formulation was analyzed for various physical parameters, results are showed in Table No.8. No 
major difference was found between evaluated parameters before and after ageing / storage and all are in acceptable 
limits 
Table 8: Evaluation parameters of stability batch (B7) 
Evaluation parameters 
 
Before stability 
Storage 
After 3 months 
storage 
Hardness (kg/cm2) 5.5±0.0 5.2±0.15 
Friability (%) 0.054±0.0 0.051±0.00 
Weight variation (mg) 405.66± 0.57 403.66 ± 0.5 
Disintegration time (sec) 91 ± 0.57 89 ± 1 
Drug content (%) 98.90 ± 0.58 97.83 ± 1.0 
Percent drug release  96.49 ± 0.49 95.28 ± 0.49 
The data are presented as mean value ± S.D. (n = 3) 
 
 
CONCLUSION:  
A biphasic drug release can be obtained by using 
bilayer tableting technology which involved 
compression of immediate and sustained release layer 
together.Successful formulation was developed having 
floating lag time as low as 14 sec and drug release was 
sustained up to 12 hrs.  The variables HPMC K200M 
and Xanthan Gum evaluated in this study exhibited 
significant effect on the responses FLT and B7 of the 
formulations; however the NaHCO3 markedly affected 
the FLT while the HPMC K200M affected the release 
profile of Dilitzam . 
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